Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.74 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.62 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.62 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358775 | 0.86 | HDAC8 (0.97) | HDAC8DPP8DPP7DPP9KMT2A | |
| SCHEMBL1358772 | 0.86 | HDAC8 (0.97) | HDAC8DPP8DPP7DPP9KMT2A | |
| SCHEMBL22428331 | 0.82 | HDAC8 (0.63) | HDAC8DPP8DPP7DPP9NLN | |
| SCHEMBL14812392 | 0.80 | HDAC3 (0.64) | HDAC8DPP8DPP7DPP9NLN | |
| SCHEMBL1244203 | 0.80 | HDAC8 (0.54) | HDAC8DPP8DPP7DPP9KMT2A | |
| SCHEMBL20569237 | 0.79 | HDAC8 (0.60) | HDAC8DPP8DPP7KMT2ANLN | |
| SCHEMBL20569239 | 0.79 | HDAC8 (0.60) | HDAC8DPP8DPP7KMT2ANLN | |
| SCHEMBL5432803 | 0.79 | DPP7 (0.69) | HDAC8DPP7NPC1 | |
| SCHEMBL8324111 | 0.77 | ACE (0.58) | HDAC8KMT2AACEKDM4EALDH1A1 | |
| SCHEMBL14392412 | 0.77 | DPP8 (1.00) | HDAC8DPP8DPP7DPP9NLN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1758920-A1 | BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS | MPEX PHARMACEUTICALS, INC. (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | REMPEX PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005113579-A1 | BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS | MPEX PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | HDAC8 535/4885DPP8 1252/4885DPP7 1233/4885 |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | ABCB11, ABCB1, ABCC1 | HDAC8 779/4885DPP8 983/4885DPP7 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.